<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1405-9940</journal-id>
<journal-title><![CDATA[Archivos de cardiología de México]]></journal-title>
<abbrev-journal-title><![CDATA[Arch. Cardiol. Méx.]]></abbrev-journal-title>
<issn>1405-9940</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Cardiología Ignacio Chávez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1405-99402015000400270</article-id>
<article-id pub-id-type="doi">10.1016/j.acmx.2015.01.004</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Heart rate and use of &#946;-blockers in Mexican stable outpatients with coronary artery disease]]></article-title>
<article-title xml:lang="es"><![CDATA[Ritmo cardíaco y empleo de beta bloqueadores en pacientes ambulatorios estables mexicanos con enfermedad arterial coronaria]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Alcocer-Gamba]]></surname>
<given-names><![CDATA[Marco Antonio]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Sánchez]]></surname>
<given-names><![CDATA[Carlos]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Verdejo-Paris]]></surname>
<given-names><![CDATA[Juan]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ferrari]]></surname>
<given-names><![CDATA[Roberto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[Kim]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Greenlaw]]></surname>
<given-names><![CDATA[Nicola]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Steg Philippe]]></surname>
<given-names><![CDATA[Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A9 "/>
<xref ref-type="aff" rid="Af1"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto de Corazón de Querétaro  ]]></institution>
<addr-line><![CDATA[Querétaro ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,CLARIFY  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Sociedad Mexicana de Cardiología  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Instituto Nacional de Cardiología "Ignacio Chávez"  ]]></institution>
<addr-line><![CDATA[Cd México ]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af5">
<institution><![CDATA[,University Hospital of Ferrara Department of Cardiology and LTTA Centre ]]></institution>
<addr-line><![CDATA[Cotignola ]]></addr-line>
<country>Italy</country>
</aff>
<aff id="Af6">
<institution><![CDATA[,Royal Brompton Hospital  ]]></institution>
<addr-line><![CDATA[London ]]></addr-line>
<country>United Kingdom</country>
</aff>
<aff id="Af7">
<institution><![CDATA[,University of Glasgow  ]]></institution>
<addr-line><![CDATA[Glasgow ]]></addr-line>
<country>United Kingdom</country>
</aff>
<aff id="Af8">
<institution><![CDATA[,INSERM  ]]></institution>
<addr-line><![CDATA[Paris ]]></addr-line>
<country>France</country>
</aff>
<aff id="Af9">
<institution><![CDATA[,Université Paris Diderot  ]]></institution>
<addr-line><![CDATA[Paris ]]></addr-line>
<country>France</country>
</aff>
<aff id="A10">
<institution><![CDATA[,Hôpital Bichat  ]]></institution>
<addr-line><![CDATA[Paris ]]></addr-line>
<country>France</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2015</year>
</pub-date>
<volume>85</volume>
<numero>4</numero>
<fpage>270</fpage>
<lpage>277</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1405-99402015000400270&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1405-99402015000400270&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1405-99402015000400270&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  Objective:  To evaluate the use of &#946;-blockers and to monitor heart rate in Mexican patients with coronary artery disease.  Methods:  CLARIFY is an outpatients registry with stable CAD. A total of 33,283 patients from 45 countries were enrolled between November 2009 and July 2010 from which 1342 were Mexican patients.  Results:  The mean HR pulse was 70 bpm (beats per minute). Patients in Mexico were compared with the remaining global CLARIFY population. Patients in Mexico had a higher incidence of acute myocardial infarction and percutaneous coronary intervention, and lower incidence of revascularization surgery compared with the remaining CLARIFY population. More often, Mexican patients presented with diabetes, but less often hypertension and stroke. These patients were split into three mutually exclusive groups of HR &#8804;60 (N = 263), HR 61-69 (N = 356) and HR &#8805;70 (N = 722). Patients with elevated HR had a higher incidence of diabetes and higher diastolic blood pressure on average than those with controlled HR. Regarding the use of &#946;-blockers, they were used in 63.3% of patients, 2.7% showed intolerance or contraindication to treatment to monitor heart rate, and ivabradine was used in 2.3%. Out of approximately 849 patients receiving treatment of &#946;-blockers, 52.1% had &#8805;70 bpm HR.  Conclusions:  In a large proportion of Mexican patients with stable coronary disease the HR remain elevated, &gt;70 bpm, even with the use of &#946;-blockers; this requires further attention.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  Objetivo:  Evaluar en pacientes con enfermedad coronaria estable, el uso de beta-bloqueadores y la frecuencia cardiaca.  Métodos:  El estudio CLARIFY es un registro internacional de pacientes ambulatorios con enfermedad coronaria estable. Se incluyeron un total de 33,283 pacientes de 45 países durante el periodo de noviembre de 2009 a julio de 2010; de estos, 1342 pacientes fueron mexicanos.  Resultados:  La frecuencia cardiaca (FC) media fue de 70 lpm (latidos por minuto). Se compararon los pacientes mexicanos con la población internacional incluida en el estudio. Los primeros tuvieron una mayor incidencia de infarto agudo del miocardio e intervención coronaria percutánea y menor incidencia de cirugía de revascularización comparado con la población mundial. La población Mexicana presentó mayor incidencia de diabetes pero menor incidencia de hipertensión y EVC. A estos se les dividio en tres grupos mutuamente excluyentes FC &#8804;60 (N = 263), FC 61-69 (N = 356) y FC &#8805;70 (N = 722). Los pacientes con FC elevada presentaron mayor incidencia de diabetes, y un registro mayor de tensión arterial sistólica comparado con aquellos con FC controlada. Respecto al uso de beta bloqueadores estos se administraron a 63.3% de los pacientes; el 2.7% mostró intolerancia o contraindicación al tratamiento con estos fármacos. Se administró ivabradina al 2.3% de los pacientes. De los 849 pacientes que recibieron tratamiento con beta-bloqueadores, el 52.1% mostró FC de &#8805; 70 lpm.  Conclusiones:  La gran mayoría de los pacientes mexicanos con enfermedad coronaria estable la FC permaneció elevada, &gt;70 bpm, aun con el uso de beta bloqueadores.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Heart rate]]></kwd>
<kwd lng="en"><![CDATA[&#946;-Blockers]]></kwd>
<kwd lng="en"><![CDATA[Stable coronary artery disease]]></kwd>
<kwd lng="en"><![CDATA[Mexico]]></kwd>
<kwd lng="es"><![CDATA[Frecuencia cardiaca]]></kwd>
<kwd lng="es"><![CDATA[Beta bloqueadores]]></kwd>
<kwd lng="es"><![CDATA[Enfermedad coronaria estable]]></kwd>
<kwd lng="es"><![CDATA[México]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Mortality by cause for eight regions of the world: Global Burden of Disease Study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[C.J.]]></given-names>
</name>
<name>
<surname><![CDATA[Lopez]]></surname>
<given-names><![CDATA[A.D.]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet.]]></source>
<year>1997</year>
<volume>349</volume>
<page-range>1269-76</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Expanding priorities - confronting chronic disease in countries with low income]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[G.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med.]]></source>
<year>2007</year>
<volume>356</volume>
<page-range>209-11</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart rate management in coronary artery disease: the CLARIFY registry]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[P.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2009</year>
<volume>11</volume>
<page-range>D13-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Diaz]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Bourassa]]></surname>
<given-names><![CDATA[M.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Guertin]]></surname>
<given-names><![CDATA[M.C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>967-74</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Influence of heart rate on mortality after acute myocardial infarction]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hjalmarson]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Gilpin]]></surname>
<given-names><![CDATA[E.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Kjekshus]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol.]]></source>
<year>1990</year>
<volume>65</volume>
<page-range>547-53</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kolloch]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
<name>
<surname><![CDATA[Legler]]></surname>
<given-names><![CDATA[U.F.]]></given-names>
</name>
<name>
<surname><![CDATA[Champion]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2008</year>
<volume>29</volume>
<page-range>1327-34</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resting heart rate in cardiovascular disease]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Borer]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Camm]]></surname>
<given-names><![CDATA[A.J.]]></given-names>
</name>
</person-group>
<source><![CDATA[J Am Coll Cardiol.]]></source>
<year>2007</year>
<volume>50</volume>
<page-range>823-30</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[P.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet.]]></source>
<year>2008</year>
<volume>372</volume>
<page-range>817-21</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bohm]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Swedberg]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Komajda]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet.]]></source>
<year>2010</year>
<volume>376</volume>
<page-range>886-94</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resting heart rate as a low tech predictor of coronary events in women: prospective cohort study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsia]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Larson]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ockene]]></surname>
<given-names><![CDATA[J.K.]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ.]]></source>
<year>2009</year>
<volume>338</volume>
<page-range>b219</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
<name>
<surname><![CDATA[Pascual]]></surname>
<given-names><![CDATA[A.V.]]></given-names>
</name>
<name>
<surname><![CDATA[London]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>1971</year>
<volume>44</volume>
<page-range>413-8</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebocontrolled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tardif]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ponikowski]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Kahan]]></surname>
<given-names><![CDATA[T.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2009</year>
<volume>30</volume>
<page-range>540-8</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Borer]]></surname>
<given-names><![CDATA[J.S.]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Jaillon]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>2003</year>
<volume>107</volume>
<page-range>817-23</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Efficacy of ivabradine, a new selective I(f) inhibitor, compared with atenolol in patients with chronic stable angina]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tardif]]></surname>
<given-names><![CDATA[J.C.]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Tendera]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2005</year>
<volume>26</volume>
<page-range>2529-36</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Importance of heart rate in determining beta-blocker efficacy in acute and long-term acute myocardial infarction intervention trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjekshus]]></surname>
<given-names><![CDATA[J.K.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Cardiol.]]></source>
<year>1986</year>
<volume>57</volume>
<page-range>F43-9</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart rate as a therapeutic target in heart failure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kjekshus]]></surname>
<given-names><![CDATA[J.K.]]></given-names>
</name>
<name>
<surname><![CDATA[Guillestad]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>1999</year>
<volume>1</volume>
<page-range>H64-9</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[beta Blockade after myocardial infarction: systematic review and meta regression analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freemantle]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
<name>
<surname><![CDATA[Cleland]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
<name>
<surname><![CDATA[Young]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
</person-group>
<source><![CDATA[BMJ.]]></source>
<year>1999</year>
<volume>318</volume>
<page-range>1730-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Heart rate, ischaemic heart disease, and sudden cardiac death in middle-aged British men]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shaper]]></surname>
<given-names><![CDATA[A.G.]]></given-names>
</name>
<name>
<surname><![CDATA[Wannamethee]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
<name>
<surname><![CDATA[Macfarlane]]></surname>
<given-names><![CDATA[P.W.]]></given-names>
</name>
</person-group>
<source><![CDATA[Br Heart J.]]></source>
<year>1993</year>
<volume>70</volume>
<page-range>49-55</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Predicting sudden death in the population: the Paris Prospective Study I]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jouven]]></surname>
<given-names><![CDATA[X.]]></given-names>
</name>
<name>
<surname><![CDATA[Desnos]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
<name>
<surname><![CDATA[Guerot]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<source><![CDATA[Circulation]]></source>
<year>1999</year>
<volume>99</volume>
<page-range>1978-83</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[High heart rate: a risk factor for cardiovascular death in elderly men]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Palatini]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Casiglia]]></surname>
<given-names><![CDATA[E.]]></given-names>
</name>
<name>
<surname><![CDATA[Julius]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<source><![CDATA[Arch Intern Med.]]></source>
<year>1999</year>
<volume>159</volume>
<page-range>585-92</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Resting heart rate is a risk factor for cardiovascular and noncardiovascular mortality: the Chicago Heart Association Detection Project in Industry]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Greenland]]></surname>
<given-names><![CDATA[P.]]></given-names>
</name>
<name>
<surname><![CDATA[Daviglus]]></surname>
<given-names><![CDATA[M.L.]]></given-names>
</name>
<name>
<surname><![CDATA[Dyer]]></surname>
<given-names><![CDATA[A.R.]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Epidemiol.]]></source>
<year>1999</year>
<volume>149</volume>
<page-range>853-62</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Benetos]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Rudnichi]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[F.]]></given-names>
</name>
</person-group>
<source><![CDATA[Hypertension]]></source>
<year>1999</year>
<volume>33</volume>
<page-range>44-52</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[P.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Lancet.]]></source>
<year>2008</year>
<volume>372</volume>
<page-range>807-16</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[K.]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
<name>
<surname><![CDATA[Steg]]></surname>
<given-names><![CDATA[P.G.]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur Heart J.]]></source>
<year>2009</year>
<volume>30</volume>
<page-range>2337-45</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
